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population in Italy. Reducing unnecessary antibiotic we in children has
become a public health priority in our country. In order to limit the risk of
emerging resistant bacteria and contain costs. it is urgent to educate
paediatricians in the rational use of antibiotics.
IMo04SI Measuring the quality of an outpatient and home
intravenous antibiotic therapy (OHPAl) programme: Use of an
Intematlonal Registry
D. Nathwani,J. Morrison, G. Barlow, A. Tice
Infection & Immunodeficiency Unit, Tayside University Hospitals Trust,
Dundee, United Kingdom; Tachoma, USA
Objectives: 1) To describe a method for continuos quality measurement ofa
clinical programme providing a regional OHPAT service. This system
which has now been operational for more than 20 months. The integrated
care pathway (ICP) used on all patients incorporates a number of key
measures of quality-patient clinical outcome and satisfaction, laboratory
(microbiology) outcome and economic outcome. Some of the generic data
are currently being incorporated into an International OPAT Registry
which aims 2) to provide an international database for determining the most
clinically and cost-effective regimens based on measurable outcome data
and. provide benchmark outcomes for providers.
Results: Number of patients treated: 183; Principle diagnosis: Skin& soft
tissue infections 51.5%. bone and joint infections 22.8%. Endocarditis;
others. Home (self administered) v Outpatient (nurse administered): 40%
v 57%. Clinical outcome: Cure/improving 94%, No Change 2%. Worse 4%.
Microbiological Outcome: 20% Culture positive-one patient had persisting
organism post-therapy. Drug related adverse reactions: 6%. Unscheduled
hospital readmission: 7.5%; Economic outcome: 2300 inpatient bed days saved;
additional cost of drugs < £12/day. Patient satiifaction: High (specific data
will be presented). Collection of such outcome measures locally and
internationally should be an integral part of an OHPAT quality assurance
programme and the International Registry will allow benchmarking and
comparisons of etfectiveness.
IMo046IResource use and cost of care for patients
hospitalized with Community Acquired Pneumonia (CAP)
W. Russell, R. Segal. F. Wang. D. Yin, T. Johns, J. Orrick
University ofFlorida, Pharmacy Health Care Administration, Gainesville
Florido 32610, United States
Objective: To examine inpatient resource use and cost of care for patients
with CAP in real-world practice settings.
Methods: A multicenter observational study was conducted in Florida
between July 1997 and October 1999. Hospitalized adult patients (> = 18
years) started on antimicrobial therapy for suspected or confirmed commu-
nity-acquired pneumonia were enrolled in the study. Exclusion criteria were
immunosuppression, cystic fibrosis and hospitalization in prior 2 weeks.
Information on patient demographic characteristics. risk class. resource use.
economic data and outcome measures were collected.
Results: 69 patients were enrolled in the study. Average age was 62.8 ± 17.2
(range 23-92); 58.9% were female. The number (%) of patients in risk
classes I-V according to Fine et al. (NEJM 1997) were 9 (13%). 24 (34.8%).
19 (27.5%), 14 (20.3%) and 3 (4.3%) respectively. Average time from ER
admission to lst dose ofantibiotic was 7.5 hours. Most frequently prescribed
antibiotics included azithromycin (29.9%), ceftriaxone (16.8%) and levo-
ftoxacin (16.4%). 40 patients received a beta-lactam/macrolide or macrolide/
quinolone. Average length of antibiotic therapy was 5.6 ± 3.2 days.
Average hospitalization cost excluding physician cost was S4,024, with
hospital room/board accounting for the largest percentage (85%), followed
by laboratory (8%), drugs (4%), radiology (2%) and respiratory (1 %). 66%
of patients received antimicrobial therapy consistent with Bartlett and
Mundy guideline (NEJM 1995) and these patients incurred lower costs
(S3,363/patient) compared to patients receiving therapy inconsistent with
guideline ($4,986/patient).
Conclusion: Understanding the processes of care in real-world practice
settings is important for improving the quality and cost-effectiveness of
care for hospital patients with CAP.
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IMoP230IUse and cost of antibiotics in a long term care
facility versus community teaching hospital in Northern Israel
V. Rozenfeld.J. Ben Israel, R. Raz l
Shoham Geriatric Center, Pardes Hanna; 'Haemek Medical Center, AjUla,
Israel
objectives: To evaluate the use and cost ofantibiotics in a Long Term Care
Facility (LTCF) with 970 beds and to compare them with a Community
Teaching Hospital (CTH) with -440 beds.
Methods: A three-point prevalence survey was performed between 7/97-6/
98 in both hospitals in order to evaluate the number of pts receiving
antibiotics. The use of antibiotics was evaluated by the Defined Daily
Dose (DOD) 1,000 hospitalization days (hd) and the cost in US S/I,OOO hd.
Results: 5.9% of the LTCF inhabitants and 24.7% of the CTH in pts
received antibiotics during the three-point prevalence survey. In the LTCF
29% of the total antibiotics prescribed were administered intravenously in
contrast to 53% in theCTH. The total DDD/l,OOOhdin the LTCF was 87.4
and in the CTH 661, with the cost of the antibiotics being 257 USS/l.000 hd
in the LTCF and 4436 USS/l,OOO hd in the CTH.
conduslons: The use and cost of antibiotic.. in a CTH is considered higher
than in a LTCF. Even though this was the expected conclusion. this is the
first study to compare antibiotic "consumption" between a CTH and a
LTCF.
IMoP231I AdHOC: Advisory group on home-based and
outpatient care. Results of a survey of OHPAT practice in the EU
and beyond
D. Nathwanil,J. -J. Zambrowski2, I. HardingJ
'Tayside University Hospital Trust, Dundee, United Kingdom; 2Hopital
Bichat, Paris, France; JMicron Research, Cambs, United Kingdom
Objectives: An advisory group has been formed to facilitate and promote
home-based and outpatient care, comprising members from EU and other
non-US countries. We report the results ofa survey ofoutpatient and home
parenteral antibiotic therapy (OH PAT) amongst members of the group.
Methods: Members completed a questionnaire on perceptions and actual
OHPAT practice in their countries.
Results: Group members from 13 countries participated, 6 ofwhom (46%)
already run an OHPAT service. OHPAT was both hospital and commu-
nity-based in 10 (77%) countries. The medical specialties most involved
were infectious diseases (all countries). haematology, general practice and
orthopaedics. Use ofOHPAT was widespread in some countries (eg. Italy)
but less well accepted in others. mostly because of financial constraints.
Formal survey data of OHPAT we exist in only 4 countries of the 13
reported here (Netherlands, UK, Italy, Brazil). OHPAT services were
controlled mostly by individuals or institutions, rather than by government
or reimbursement/insurance agencies. All participants considered that
OHPAT would increase during the next five years, given changes in funding
or reimbursement systems. The main barriers to acceptance were: lack of
organisation, lack of clinical trial data and funding issues.
Condusions: OHPAT is widespread outside the USA, but barriers exist to
its acceptance and expansion elsewhere. In our current cost-conscious
healthcare environment. it is important to find new ways of delivering
care which are Cost-effective and improve quality of life for patients and
carers. The group aims to provide a forum for developing generic and local
guidance for OHPAT and hopes to collaborate with the ENIS Group with a
view to promoting OHPAT in Europe and beyond.
IMOP232! Pharmacoeconomic evaluation of antibiotics in
acute sinusitis in adults
O. Karpov, A. Zaytsev, YU. Ignatov
Institute ofPharmacology, Saint-Petersburg, Russian Federation
Objectives: A number ofantimicrobial agents are effective in the treatment
ofacute sinusitis. Economic evaluation is necessary for best practice recom-
mendations.
Methods: The economic outcomes of azithromycin (AZ), midecamycin
(Me). co-amoxic1av (CA) and cefadroxil (CF) treatment were studied in
randomised investigation among 160 adults with confirmation of acute
sinusitis. 50 patients received AZ at 500 mg once a day during 3 days. 30 -
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MC at 400 mg tid, 50 - CA at 625 mg tid, and 30 - CF at 500 mg bid during
10 days. The direct (the hospitalisation outlay and antibiotics' course price)
and additional costs (cost after the change of antimicrobial in case of initial
treatment failure) were calculated.
Results: The cure rates were: for AZ and CA - 94%, for MC - 90% and for
CF - 83%. The direct cost was least at AZ group ($70.3 per patient) and
biggest - in CA group ($105.9). It was $94.8 and $98.8 in CF and MC groups
accordingly. The total (direct and additional) cost was $70.6 (AZ), $106.6
(CA), $98.1 (CF), $102.2 (MC) per patient. Cost-effectiveness ratio for AZ
was the most attractive among others antibiotics and it was 0.74 (p < 0.01).
Same indexes for CA, CF and MC were 1.11; 1.14 and 1.09 accordingly.
Conclusions: Azithromycin has the better economic outcomes in compar-
ison with co-amoxiclav, cefadroxiJ and midecamycin that may be used for
determination of acute sinusitis trearment regimen.
Table 1. Average cost PPPM (1996/1999)
Population
No. comorbiclities 0 1-3 4+ average
N 361/239 446/578 31/68 838/885
Noo-ART drug 520/5108 5122/S200 5315/$648 S85/5144
ART drug 555/1457 5207/$601 5259/$803 5143/5579
Hosp 550/517 5248/S81 51282/5510 5200/S85
HHC 594/145 $210/S85 51121/587 1224/161
Other $58O/S83 $670/5204 51892/5717 1677/S306
Total S8OO/5710 51516/51172 14869/52765 51329/51174
Conclusions: Since 1996 substantial decreases in HIV-related mortality have
occurred. As pts. live longer with HlV, comorbidities have increased, but
total cost of care has declined. Additional longitudinal studies are needed to
confirm these results.
IMoP23S1 Increasing costs of HIV care associated with
successive losses of viral suppression
). Stansell',). Barrett2, C. de Guzman2, C. Holtzer3, D. Lapins2
'Positive Health Program, San Francisco General Hospital, San Francisco, CA;
zClinical Partnas, San Francisco, CA, United Stales; JVisible Genetics, Paris,
France
Objective: To determine costs ofHIV care associated with each loss ofvinl
suppression, defined as viral load (VL) < 400 copies/mL.
Methods: We evaluated an 811-patient, longitudinal database containing
clinical and cost data (hospitalization, pharmacy, laboratory, skilled nursing
facilities, home health, professional fees and infusion costs) from 1/1/96 to 6/
30/99. Patient population was insured, 95% mate and seen by private
practitioners. Costs were calculated by month, stratified by VL and by
number oftherapeutic failures (defmed as 2 successive VL > 1000 copies/ml,
2:;2 weeks apart). Patients were followed longitudinally. Statistical signifi-
cance measured by Student's t-test (defined by p < 0.05).
Results
ARV failure = 1
PPPM cost Hospital cost Drug cost
Hospital PPPM Drug PPPM
P < 0.05
$883
S889
51190
P < 0.05
P < 0.05
S48
5192
$224
TotalPPPM
51206
51448
51779
P = 0.05
P = 0.014
Aotirerroviral (ARV)
failure category
Failure category
No ARV failure (n = 269)
ARV failure = 1 (0 = 572)
ARV failure > 1 (n = 98)
No ARV failure
ARV failure > 1
I. Durand-Zaleski', S. Gabriel2}. Diner2, A. Tarantola3, E. Bouver4
lHopital Henri Mondor, Creteit; Health Economit:s Sanofi-Synthelabo,
Bagneux; JGERES, Faculte Bichat, Paris; 4Hopital Bichat, Paris, France
Objective: Subcutaneous injections account for an increasing share of total
needlestick injuries. The objective was to document the possible cost-savings
related to the introduction of a protected needle (safety shaft) used to
administer LMWH.
Methods: we estimated the frequency ofneedlestick injuries attributable to
treatment with LMWH from both published and CCLIN data and modeled
a countrywide estimate. The total societal cost of managing a needlestick
injury was assessed assuming that all the recommended procedures were
followed. This theoritical cost was put in perspective with observed data
(GERES study on post-exposure prophylaxis in 1998).
Results: The total calculated societal cost of testing the source patient and
healthcare worker, of prophylactics and workdays lost was assessed to be
superior to $2,000. However, the large discrepancy between recommended
and actual practice led to significant reductions in costs, mostly linked to the
absence of sick-leaves and systematic prophylaxis.
Conclusion: The use of a safer device for LMWH injections may result in
cost-savings by avoiding the costs of needlestick injuries management.
Although rhe costs avoided were shown to be lower in reality than in
theory, our approach was conservative as the costs related to the risk ofviral
infection were not included. In addition, the medical benefits of reducing
exposure to blood should be added to the potential costs-savings.
IMoP233I Costs avoided by using a safety device for
subcutaneous injections of Low Molecular Weight Heparin
(LMWH)
IMoP234I Comorbidity and cost of care in HIV+ patients (pts.)
1996-1999
Conclusions: Despite successful salvage therapy, total PPPMs significantly
increased as the number of therapeutic failures increased (p < 0.0001).
Analysis of costs that comprise the total cost of core reveals drug costs
account for the majority of cost increases for patients who tailed initial
HAAS. Costs of HIV care are minimized by the maintenance of undetect-
able viral load.
M. K. Rawlings', R. Siaker2, E. Hamel2, D. Lafins2
1Parkland Health & Hospital Systml, Dalas, TX; Clinical Partners, San
Francisco, CA, United States
Objective: To determine trends in no. of comorbidities and cost of care in
HIV + pts. between 1996 and 1999.
Methods: Paid insurance claims for 1,389 pts. were analyzed for diagnosis,
drug, and procedure codes indicating 17 key comorbidities (treatment (tx)
w/antidepressants, tx w/antipsyehoties, cardiac or rhythmia, cervical dys-
plasia, diabetes, heart failure, hepatitis, herpes, hyperlipidemia, hyperten-
sion, ischemic heart disease, kidney stones, lipodystrophy, necrosis, non-
PCP pneumonia, pregnancy, chronic respiratory disease, tuberculosis).
Average cost of care per pt. per month (PPPM) was determined for 1996
and 1999.
Results: Average no. of comorbidities per pt. Increased from 0.99 to 1.46,
while cost of care decreased from $1329 to $1174 from 1996 to 1999.
Increases in drug costs (bath ART and non-ART) have been offset by large
decreases in non-drug costs, including a 58% reduction in hospital and 73%
reduction in home healthcare (HHC). Average cost in all categories increases
as no. of comorbidities increases (see table).
IMoP236! Use of Highly Active Antiretroviral Therapy
(HAART) among 483 patients in Italy
D. Yin l , F. Tediosi2,DiCinti02, F. Parazzini2, 1. Garattini2
1Merck & Co., Inc. Whitehouse Station, United States; 2Mario Negri Institute
for Pharmaceutical ResearchItaly
Objective: HAART that includes at least one protease inhibitor in combi-
nation with reverse transcriptase inhibitors has become the most important
strategy for treating HIV infection. The objective ofthis study is to describe
patterns of HAART use among 483 Italian patients.
Methods: A multicenter, prospective observational study was conducted in
five Italian hospitals between June 1997 and June 1998. Patients were
stratified by CD4 cell count and AIDS status and were followed prospec-
tively for one year. Data were collected every three months by predesigned
questionnaire. Information collected included patient characteristics, CD4
cell count, viral load, opportunistic illnesses, healthcare resource utilization,
and employment status.
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Results: 483 patienu were enrolled in the study. The percentage ofpatients
receiving HAART increased from 37.1 % to 56.6% among patients with
CD4 cell count between 200 and 500 copies/mm3 and 15.3% to 31.5%
among patients with CD4 > 500 copies/mm3. Among patienU with AIDS
defining illness (AD!) and CD4 cell count less than 200 copies/mm3 at
enrolment, the percentage of patients receiving HAART remained stable.
% ofpatients remain employed
Patient dioeaoe
stage at enrolment
% Patients treated with HAART at any time
during period
0-3 montm
4-6montm
7-9montm
9-12 months
Patients on
HAART
81.1 % (133/164)
79.9 (131/164)
79.9 (131/164)
76.8 (126/164)
Patients not on
HAART
76.6% (59f77)
66.2 (51/77)
63.6 (49/77)
61.0 (47f77)
0-3 4-6 7-9 10-12
montm montm montm months
Patients with AIDS defining
illness (ADI); n - 122 88.5% 82.8% 85.3% 82.0%
CD4 < 200 copies/mm3, no
AD!; n = 114 68.4 71.9 62.3 64.0
CD4: 200-500 copies/mm3;
n = 123 37.1 51.6 53.2 56.5
CD4 > 500 copies/mm3,
n = 124 15.3 21.8 28.2 31.5
Conclusions: HAART could be considered under-utilised among patients
without AIDS defining illness in Italy betweenJune 1997 andJune 1998.
IMoP237I Patients on Highly Active Antiretroviral Therapy
(HAART) are more likely to remain employed in Italy
D. Yin!, F. Tediosi2,DiCinti02, F. Parazzini2, L. Garattini
I MeTck & Co., Inc. Whilehouse Station, United States; 2Mario Negri Institute
for Pharmaceutical Researchltaly
Objective: To estimate the association between HAART and employment
status among HIV-positive patients.
Methods: A multicenter, prospective observational study was conducted in
five hospitals located in three different regions ofItaly (1 from the South, 2
from Centre, 2 from the North) betweenJune 1997 andJune 1998. A total of
483 patients were stratified by CD4 cell count and AIDS status and ware
followed prospectively for one year. Data were collected every three months
by predesigned questionnaire. Information collected included patient char-
acteristics, CD4 cell count, viral load, opportunistic illnesses, healthcare
resource utilization, and employment status.
Results: At enrolment 241 ofthe 483 patients (50%) were an employee, self-
C:nl.ploycd, or a tcntporary W"orker. P3tientlt 'Who rect'!-iveO HAART were
more likely to remain employed during the one-year follow-up period (see
table). Multivariate logistic regression indicated that the likelihood of
remaining employed was associated with HAART (Odds Ratio = 2.9, P
= 0.0001), status ofAIDS defining illness (OR = 0.36, P = 0.0001) or CD4
< 200 cells/mm3 at enrolment (OR = 0.43, P = 0.0002).
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IWeP260IFirst description of the human granulocytic
ehrlichiosis in Croatia
L]. Misic-Majerus1, N. Bujicl , V. Madjaric', V.Janes-Poje'
1Department of Infeaious Diseases; General Hospital, Koprivnica, Croatia
Objective: To present epidemiological, clinical, laboratory characteristics
and diagnostic analysis of patients suffering from Human granulocytic
ehrlichiosis (HGE).
Methods: Fint patients affected with HGE, who have been hospitalised at
the Department of Infectious Diseases of the General Hospital in Kopriv-
nica-Croatia, during the 1998, were included in the analysis. Three man and
one woman aged from 17-67 were infected. The clinical picture,laboratory
findings and course of disease have been described in details. Specific
antimicrobial therapy was not administrated. Serological methods ofindir-
ect immunofluorescence assay (lFA) were used for diagnostic confirmation.
Results: HGE was self-contained disease in two patients. Clinically, it was
presented as non-specific. flu-like acute, febrile illna with leukopenia,
trombocytopcnia and moderately elevated aminotransferase values. In two
Conclusions: Employed HIV-positive patients who received HAART were
2.9 times more likely to remain employed than patients receiving non-
HAART therapy or no antiretroviral therapy.
IMoP23S1 Cost outcomes for HIV-associated wasting: Initial
treatment with somatropin V5. initial treatment with other
wasting treatments
V. Cafaro', C. de Guzman2• D. Gary2, E. Hamee, R. Slaker2, M. Lange2•
D. Lapins2
I Wellspring Medical Croup, San Francisco, CA; 2Clinkal Partners, San
Francisco, CA, United Slates
Objective: To analyze cost outcomes for patients receiving somatropin,
stratified by prior treatment for AIDS-related wasting.
Methods: Clinical Parmen (CP) is a national disease management company
providing data support and HIV case management for managed core
organizations. The CP database contains clinical data from chart audits
and electronic claims data. In an analysis of patients with AIDS-related
wasting, 38 patients began somatropin treatment between 1/1/1997 and 6/
30/1999. 18 patients received treatment for wasting using some combination
of testosterone, oxandrolone, and/or dronabinol prior to their treatment
with somatropin. Patients were stratified into "First-line somatropin" and
"First-line Other Wasting Treatment (OWT)" groups, and analyzed for
cost outcomes in an intent-to-treat analysis. All patients had evidence of
wasting syndrome (defined as loss of ~10% of body weight) by an HIV
dietitian; all were on stable antiretroviral therapy. CD4+ counts and viral
suppression rates before wasting treatment were comparable between the
groups.
Results: While average PPPM costs between the groups were similar prior
to wasting treatment, differences were evident during end afrer treatment
with somatropin. For patients in the First-line somatropin group, average
cost PPPM declined 27% ($1,859 to $1,356) following sornatropin treat-
ment. while costs rose 187% ($1,770 to $5,080) in the First-line OWTgroup.
Conclusions: In this cohort, patients initially treated with somatropin had
better cost outcomes than patients who initially received other wasting
treatment. Before firm conclusions can be drawn, a prospective trial
evaluating initial somatropin use vs. somatropin as secondary and cost
outcomes treatment should be initiated.
patients it was a coinfection. In one patient HGE was associated with Tick-
borne encephalitis (TBE) and in the another with Lyme disease (LB). Testing
sera for antibodies for Ehrlichia equi and HGE causative pathogen showed a
quadruple increase in the acute and covalescent phase of the disease.
Conclusion: This study presents fint proven patients with HGE in Croatia.
IWeP261! Sensitive PCR method to detect Babesia dlvergens
L. V. von Stedingkl, M. Gurtelschmid', M. Granstrom l ,]. Gray2
'Clin. Microbiol. Karol. Hosp. Stockholm, Sweden; 2Univ . College Dublin,
United Kingdom
Objectives: Babesiosis, primarily known to afflict wild and domestic
animals is being increasingly recognized as a human disease both in
Europe and in the United States. The intra-erythrocytic parasite Babesia
divergens is the predominant etiologic species in Europe and is transmitted
by the tick Ixodes ricinus. The aim ofthe study was to create a sensitive and
specific PCR method to detect B. divergens parasites in ticks and whole
blood samples.
